One year of treatment with dapirolizumab pegol reduced fatigue and disease activity in people with SLE in a Phase 3 trial.

The systemic lupus erythematosus (SLE) treatment pipeline is experiencing unprecedented expansion, driven by increasing disease awareness, rising pre ...

Researchers have found in a recent meta-analysis that belimumab is more effective than placebo in treating systemic lupus erythematosus (SLE), based on BICLA criteria. This finding ...

Dapirolizumab pegol, a novel CD40L inhibitor, is superior to placebo for achieving low disease activity and remission in ...

New research by Swansea University and Cambridge University has revealed the causes and devastating impacts of delays—that ...

A novel antibody-based drug targeting the CD40 ligand helped close to half of patients with treatment-refractory systemic ...

Six of the patients, of whom four had non-renal SLE, had follow-up of at least 24 weeks. Of those, five showed dramatic ...

Magnetic resonance imaging (MRI) findings such as inflammatory-type lesions and myelopathies are significantly associated with attribution of neuropsychiatric (NP) events to systemic lupus ...

Lupus can be debilitating and sometimes deadly for the 3 million people who have it. A treatment called CAR T appears to stop ...

Objective This study aims to evaluate the role of antiphospholipid antibodies (aPLs) in patients with SLE with heart valve ...

A team studied the differences between monogenic and nonmonogenic lupus nephritis and the predictors of end-stage kidney disease.